Lineage Cell Therapeutics (LCTX) Profit After Tax Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 91.31% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.89% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 90.66% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.56% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 37.44% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 59.34% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 31.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.91% |
| Mar 31, 2026 | -2.83% |
| Dec 31, 2025 | 28.35% |
| Sep 30, 2025 | -69.88% |
| Jun 30, 2025 | -64.97% |
| Mar 31, 2025 | 16.41% |
| Dec 31, 2024 | 51.80% |
| Sep 30, 2024 | 27.34% |
| Jun 30, 2024 | -6.35% |
| Mar 31, 2024 | -66.69% |
| Dec 31, 2023 | -63.24% |
| Sep 30, 2023 | 2.66% |
| Jun 30, 2023 | 7.10% |
| Mar 31, 2023 | 19.36% |
| Dec 31, 2022 | -12.34% |
| Sep 30, 2022 | 28.36% |
| Jun 30, 2022 | 39.16% |
| Mar 31, 2022 | -29.67% |
| Dec 31, 2021 | 13.60% |
| Sep 30, 2021 | -28.41% |